Outcome after thrombolysis and selective thoracic outlet decompression for primary axillary vein thrombosis.
OBJECTIVE
Treatment for primary subclavian-axillary vein thrombosis (SAVT) at our institution consists of thrombolysis and anticoagulation for 3 months. Thoracic outlet decompression has been performed for a small number of patients. We wanted to review the functional outcomes of patients treated in such a manner.


METHODS
The records of all patients treated for a first episode of SAVT at our hospital over the past 10 years were reviewed. Demographics, comorbidities, method of diagnosis, and treatment for SAVT were recorded. Long-term follow-up was obtained by chart review and asking patients to complete the DASH (disabilities of the arm, shoulder and hand) questionnaire that was developed by the American Academy of Orthopedic Surgeons.


RESULTS
Twenty-eight patients, 20 men and eight women, with a mean age of 36 were treated during the study period. The median time between onset of symptoms and treatment was 5.5 (range, 1-100) days. All patients had confirmation of the diagnosis by venography. Twenty-five patients received thrombolytic treatment with catheter-directed infusions of urokinase; in the other three patients the vein was chronically occluded. Twelve patients had some degree of residual stenosis and were treated with percutaneous transluminal angioplasty after thrombolysis. During the study period two patients underwent decompressive surgery. Twenty-one patients responded to the DASH questionnaire a mean of 2.9 years (range, 2 months to 8 years) after the episode of SAVT. Six (28%) of 21 patients were completely symptom free, 13 patients (62%) had DASH scores consistent with mild symptoms, and two patients had more severe symptoms. Twenty percent (4 of 21) of patients report some difficulty with work.


CONCLUSIONS
Thrombolysis, followed by selective thoracic outlet decompression on the basis of the severity of patients' symptoms can be used as a therapeutic approach to SAVT without undue morbidity. The DASH questionnaire is a useful tool to evaluate results after therapy for SAVT.
Lokanathan
R
R
Division of Vascular Surgery, University of British Columbia, Vancouver, Canada.
Salvian
A J
AJ
Chen
J C
JC
Morris
C
C
Taylor
D C
DC
Hsiang
Y N
YN
D000328:Adult; D000800:Angioplasty, Balloon; D001367:Axillary Vein / Q000000981:diagnostic imaging; D019299:Decompression, Surgical; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010960:Plasminogen Activators / Q000627:therapeutic use; D011859:Radiography; D020127:Recovery of Function; D013350:Subclavian Vein / Q000000981:diagnostic imaging; D015912:Thrombolytic Therapy; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use; D020246:Venous Thrombosis / Q000000981:diagnostic imaging / Q000601:surgery / Q000628:therapy*
D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator